Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7656330 | 0.84 | ALDH1A1 (0.40) | CHRNB2CHRNA4ALDH1A1MEN1KMT2A | |
| SCHEMBL7661155 | 0.83 | CHRNB2 (0.38) | CHRNB2CHRNA4ALDH1A1PRMT6MEN1 | |
| SCHEMBL7650781 | 0.81 | TSHR (0.30) | — | |
| SCHEMBL7106657 | 0.79 | PNP (0.39) | PNP | |
| SCHEMBL7662648 | 0.76 | HSD17B10 (0.41) | CHRNB2CHRNA4PRMT6POLB | |
| SCHEMBL7103584 | 0.76 | PNP (0.44) | PNP | |
| SCHEMBL7652140 | 0.75 | PNP (0.39) | PNPCHRNB2CHRNA4ALDH1A1MEN1 | |
| SCHEMBL7656354 | 0.74 | PNP (0.36) | PNPCHRNB2CHRNA4 | |
| SCHEMBL7654381 | 0.69 | — | — | |
| SCHEMBL7663487 | 0.69 | PNP (0.34) | PNPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6399613-B1 | N,N'-BIS(2-HYDROXYETHYL)PYRAZINE-2,5- OR -2,6-DICARBOXAMIDE; DIABETES | AVENTIS PHARMA S.A. (FR) | 2002-06-04 | — | — | US | claimed |
| US-6399613-B1 | N,N'-BIS(2-HYDROXYETHYL)PYRAZINE-2,5- OR -2,6-DICARBOXAMIDE; DIABETES | AVENTIS PHARMA S.A. (FR) | 2002-06-04 | — | — | US | disclosed |